Moderna is reporting Q3 results this morning, and the top-line numbers are almost beside the point. The stock has risen more than 600% in 2026 on the strength of its cancer pipeline. What investors need from today’s call is clarity on whether the company can afford to see that pipeline through.
Why This Stock Now
Moderna stock jumped 13% to $258.38 on Thursday ahead of Q3 earnings, lifted by a World Health Organization panel recommending that Moderna’s Ebola vaccine candidate be added to an ongoing trial, alongside continued cancer-vaccine momentum, extending a 600%-plus gain this year. The vaccine revenue story is weak by design. Analysts expect a quarterly loss of roughly $1.25 per share and revenue of approximately $890 million, both representing a decline from a year ago. That is the expectation investors should hold. What actually moves the stock is cash, pipeline progress, and 2027 spending guidance.
The Cancer Pipeline Is the Whole Thesis
At ESMO in October, Phase 3 INTerpath-001 results showed intismeran autogene cut the risk of melanoma recurrence or death by 42% when added to Keytruda. That is a randomized Phase 3 result. It is the kind of data that moves biotech valuations, and it is exactly why the stock has re-rated so sharply this year.
Intismeran is a personalized mRNA cancer vaccine developed in a collaboration with Merck. Beyond melanoma, Moderna and Merck are evaluating intismeran autogene across nine Phase 2 and Phase 3 studies covering non-small cell lung cancer, bladder cancer, and renal cell carcinoma. This is a bet on whether personalized mRNA therapy can become a true platform, not a one-indication drug.
Earlier this week, an additional catalyst emerged. Early data for mRNA-2808, Moderna’s three-in-one multiple myeloma therapy, showed four confirmed responses among 11 response-evaluable, heavily pretreated patients. Small sample, meaningful signal. Multiple myeloma is a large commercial market, and the data accelerated the pre-earnings rally.
Can Moderna Afford the Pipeline?
This is the question that matters most on today’s call. Moderna burned about $1.3 billion of free cash flow in the first half of 2026, compared with roughly $2.1 billion a year earlier. Cost cuts have helped. The company guides to $4.7 billion to $5.2 billion of cash and investments at year-end, excluding any use of the remaining $0.9 billion under its credit facility. At current burn rates, that runway carries through the most critical regulatory decisions for intismeran. Any guidance that implies accelerating spending without a corresponding revenue ramp will raise hard questions.
On the revenue side, Health Canada authorized mFLUSIVA and mCOFLU for adults 50 years of age and older on Thursday. In the U.S., the FDA approved MFLUSIVA on August 5, 2026, for adults 50 and older. A successful U.S. commercial rollout would add a revenue stream that reduces dependence on the COVID franchise and extends the cash runway.
What Could Go Wrong
Even after Thursday’s pullback, the stock trades near its highest forward sales multiple in five years, so the science matters far more than the quarter. Any signal that overall survival data for intismeran in melanoma disappoints, or that Phase 3 filing timelines slip, removes the central pillar supporting the valuation. The stock is priced for execution. It is not priced for setbacks, and biotech development rarely runs on schedule.
The Bottom Line
Moderna is no longer a vaccine story. It is a bet on personalized mRNA cancer therapy achieving regulatory approval and commercial scale across multiple tumor types simultaneously. Guidance, cash runway, and the regulatory path for intismeran are likely to set the stock’s direction in the sessions ahead, and overall-survival data remain the largest open question for the cancer franchise. Today’s quarterly results are a checkpoint. The pipeline update is what actually moves the stock.